Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting NCT06078020

PLatform Study for INTracerebral Haemorrhage (PLINTH): Community-based Feasibility Study

PLatform Study for INTracerebral Haemorrhage (PLINTH): Community-based Feasibility Study — Active Not Recruiting • Cardiology / Cardiovascular • NCT06078020.

📅 25 Jun 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
NCT ID
NCT06078020
Start
2023-10-01
Completion
2025-06-30
ClinicaliQ Trial Snapshot
  • PLatform Study for INTracerebral Haemorrhage (PLINTH): Community-based Feasibility Study — Active Not Recruiting • Cardiology / Cardiovascular • NCT06078020.
  • PLINTH Study Summary.
  • This feasibility study tests whether a platform trial design is acceptable and workable for treating brain haemorrhage stroke survivors.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this observational study is to answer three uncertainties about the design of a platform study for adults with stroke due to intracerebral haemorrhage. The main things the investigators aim to find out are: * The acceptability of a platform trial and its comparisons to brain haemorrhage survivors or their carers, and their clinicians. * Estimates of eligibility, willingness to participate, diversity, representativeness, adherence, retention, data completion, and event rates of intermediate and clinical outcomes over time for each comparison. * The most efficient platform trial design considering…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)
Cardiology / Cardiovascular · 16 Jul 2026
Netarsudil evaluation by NICE was terminated, indicating it is not recommended for routine use in NHS treatment pathways for open-angle glaucoma or…
View guideline →
Guideline
Stroke and TIA: Diagnosis and Initial Management (NICE NG128)
Cardiology / Cardiovascular · 27 Mar 2026
Use FAST recognition (Face, Arms, Speech, Time) in primary care to identify suspected stroke and arrange immediate hospital admission as a medical…
View guideline →
Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Guideline
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Cardiology / Cardiovascular · 30 Jul 2026
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers,…
View guideline →
Clinical Brief
New heart disease and strokes plan to saves thousands of lives
Cardiology / Cardiovascular · NHS England · 07 Jul 2026
A new national framework aims to reduce premature deaths from heart disease and strokes by 25% over the next decade, requiring implementation…
View brief →
Guideline
Sotatercept for treating pulmonary arterial hypertension
Cardiology / Cardiovascular · 03 Jun 2026
Sotatercept is recommended as a treatment option for pulmonary arterial hypertension (PAH) in patients who meet NICE criteria; verify patient eligibility and…
View guideline →